Skip to main content
main-content

Latest news stories

Latest news stories

26-06-2019 | Juvenile idiopathic arthritis | News

Anxiety, depressive symptoms linked to pain and disability in JIA

Anxiety and depressive symptoms are associated with pain and disability but not active joint count or biomarkers of inflammation in adolescents with juvenile idiopathic arthritis, researchers report.

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Positive secukinumab results for axial manifestations in PsA

Secukinumab improves axial manifestations in patients with psoriatic arthritis and an inadequate response to nonsteroidal anti-inflammatory drugs, primary analysis of the phase III MAXIMISE trial shows.

25-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab efficacious in PsA following one or two inadequate anti-TNF responses

Patients with psoriatic arthritis who have an inadequate response to one or two tumor necrosis factor inhibitors may benefit from ixekizumab, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

24-06-2019 | Osteoarthritis | News

Fasinumab may be a new option for osteoarthritic pain

The anti‐nerve growth factor monoclonal antibody fasinumab improves pain and function in patients with knee or hip osteoarthritis who have a history of inadequate response or intolerance to analgesics, study findings indicate.

21-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Ultra-low rituximab doses may not be appropriate in RA

A randomized trial has failed to demonstrate noninferiority of ultra-low dose rituximab to a standard low dose of the drug in patients with rheumatoid arthritis.

20-06-2019 | Kawasaki disease | EULAR 2019 | News

KAWAKINRA results support further investigation of anakinra for Kawasaki disease

The interleukin-1 receptor inhibitor anakinra merits further investigation for the treatment of Kawasaki disease, suggest findings from a phase IIa trial presented at the EULAR 2019 congress in Madrid, Spain.

20-06-2019 | Osteoarthritis | EULAR 2019 | News

Tanezumab demonstrates potential for osteoarthritis

Phase III study findings reported at the EULAR 2019 congress in Madrid, Spain, provide support for the use of tanezumab, a monoclonal antibody against nerve growth factor, to improve pain and physical function among individuals with osteoarthritis.

19-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

Brodalumab shows axial spondyloarthritis treatment potential

Brodalumab has demonstrated efficacy and appears tolerable for the treatment of axial spondyloarthritis, delegates were told at the EULAR 2019 congress in Madrid, Spain.

19-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Early RA patients with HLA-DRB1 risk alleles may benefit from abatacept over adalimumab

Patients with early moderate-to-severe rheumatoid arthritis who test positive for HLA-DRB1 shared epitope alleles may benefit more from abatacept than adalimumab, an analysis of head-to-head data indicates.

18-06-2019 | Systemic sclerosis | EULAR 2019 | News

Nintedanib reduces SSc-ILD progression across various subgroups

Nintedanib slows lung function decline in a variety of patients with systemic sclerosis-associated interstitial lung disease, suggests a subgroup analysis of data from the SENSCIS trial.

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Methotrexate withdrawal feasible with tofacitinib in patients with RA

Most patients with rheumatoid arthritis who achieve low disease activity with the Janus kinase inhibitor tofacitinib plus methotrexate can withdraw methotrexate without significant worsening of disease activity, findings from the ORAL Shift trial show.

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Filgotinib beneficial for RA patients with no prior methotrexate exposure

Filgotinib, given in combination with methotrexate, may be a promising treatment option for methotrexate-naïve patients with moderate-to-severe rheumatoid arthritis, indicate findings from the FINCH 3 trial.

17-06-2019 | JAK inhibitors | EULAR 2019 | News

EQUATOR analysis shows patient-level response to filgotinib in PsA

Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.

17-06-2019 | Juvenile idiopathic arthritis | EULAR 2019 | News

Further investigation of tocilizumab for JIA-associated uveitis may be warranted

Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial

Findings from the SPIRIT-H2H trial, presented at the EULAR 2019 congress in Madrid, Spain, have demonstrated superior efficacy of ixekizumab versus adalimumab among patients with psoriatic arthritis.

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Bimekizumab shows dual efficacy in patients with psoriatic arthritis

Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Glucocorticoid tapering recommended for RA patients responding to tocilizumab

Rheumatoid arthritis patients who achieve low disease activity with tocilizumab and low-dose glucocorticoids should be considered for glucocorticoid tapering, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

Image Credits